U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07363577) titled 'Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia' on Dec. 26, 2025.
Brief Summary: This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Schizophrenia
Intervention:
DRUG: LB-102 (50 mg tablet)
LB-102 oral tablet given for six weeks
DRUG: LB-102 (100 mg tablet)
LB-102 oral tablet given for six weeks
OTHER: Placebo
Placebo table...